The Big Picture
New data concerning Eli Lilly's obesity drug has indicated potential side effects. Separately, Revolution Medicines has reported promising results for its cancer drug. Additionally, information regarding deals involving Roche and Johnson & Johnson has been presented.
Key Facts
- 1
New data on Eli Lilly's obesity drug indicates potential side effects.
- 2
Revolution Medicines' cancer drug shows promising results.
- 3
Deals involving Roche and Johnson & Johnson were mentioned.
How Media Is Covering This
1 articleWhy It Matters
In parallel, Revolution Medicines has announced promising results for its cancer drug. The specifics of these results were not detailed in the provided summary.
The update also mentioned deals involving Roche and Johnson & Johnson, though the nature and details of these agreements were not specified.
